By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PsiOxus Therapeutics Limited 

Cherwell Innovation Centre
Unit 77, Heyford Park
Upper Heyford  Oxfordshire  OX25 5HD  United Kingdom
Phone: 44-(0)1869-238069 Fax: 44-(0)1869-238001



Company News
Imperial Innovations Release: Portfolio Company PsiOxus Signs Exclusive Worldwide License Agreement With BMS For NG-348 Its First "Armed" Oncolytic Virus 12/20/2016 9:25:43 AM
Bristol-Myers Squibb (BMY) Inks $936 Million “Armed” Oncolytic Virus Deal With PsiOxus 12/20/2016 6:37:27 AM
UK's PsiOxus Appoints Two New Execs in the U.S. in C-Suite Shakeup 9/16/2016 6:25:05 AM
PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb (BMY) 6/30/2016 6:35:36 AM
Parker Institute For Cancer Immunotherapy And PsiOxus Announce Intention To Collaborate On Tumor-Specific Immuno-Gene Therapy 4/14/2016 10:27:20 AM
PsiOxus Initiates Combination Of Paclitaxel With Oncolytic Virus Enadenotucirev In Ovarian Cancer Study 3/10/2016 10:32:14 AM
PsiOxus Appoints Dr Paolo Paoletti As Chairman Of The Board 1/7/2016 11:48:00 AM
PsiOxus Initiates Combination Study Of Merck & Co. (MRK)’s Keytruda With Oncolytic Virus Enadenotucirev 12/16/2015 11:09:24 AM
PsiOxus Scores $38.5 Million Series C 5/19/2015 6:04:14 AM
PsiOxus Therapeutics Limited To Present Promising New Data On Novel Oncolytic Immunoncology Platform At American Association for Cancer Research 2015 4/16/2015 1:05:38 PM